Clinical Trial Update: Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating olaparib in BRCA-mutated relapsed ovarian cancer after platinum-based therapy; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity | Phase 3 | Status: COMPLETED | Results posted: 2019-12-02